Print ISSN:-2581-5555

Online ISSN:-2456-9542

CODEN : IIJCDU

Article History

Received : 23-01-2023

Accepted : 15-03-2023



Article Metrics




Downlaod Files

   


Article Access statistics

Viewed: 435

PDF Downloaded: 147


A review on spinal muscular atrophy: An inherited neuromuscular disease


Full Text PDF


Review Article

Author Details : Mahendra Dwivedi*, Akansha Mishra, Manali Singh, Nagendra Singh, Anshu Tripathi, Chandra Pratap Singh

Volume : 8, Issue : 1, Year : 2023

Article Page : 22-26

https://doi.org/10.18231/j.ijcaap.2023.003



Suggest article by email

Get Permission

Abstract

Spinal muscular atrophy is an inherited neurodegenerative illness characterized by muscle wasting and loss of spinal cord motor neurons. It results from homozygous loss, translation, or mutation of the survival motor neuron 1 (SMN1) gene. Despite the lack of a cure, research has revealed potential processes explaining the disease’s molecular etiology. The SMN1 gene region’s distinctive genomic structure has been used to design treatment plans. Several stages of development have been recognized for a number of possible therapeutic agents. The standard of treatment for people having spinal muscular atrophy has evolved as a result of these and other healthcare technological advancements. In this review, we provide a comprehensive review of general introduction, types, symptoms, causes, diagnosis, and possible management of spinal muscular atrophy (SMA)..
 

Keywords: Spinal muscular atrophy, Inherited, Muscle biopsy, Mutation, Electrodiagnosis



How to cite : Dwivedi M, Mishra A, Singh M, Singh N, Tripathi A, Singh C P, A review on spinal muscular atrophy: An inherited neuromuscular disease. IP Int J Compr Adv Pharmacol 2023;8(1):22-26


This is an Open Access (OA) journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.